Marker Therapeutics (MRKR.US): The 2024 Q1 financial report achieved revenue of $1.244 million, previous value of $1.244 million; earnings per share was -0.27 US dollars, previous value of -0.57 US dollars.
Marker Therapeutics(MRKR.US)：2024年Q1财报实现营收124.4万美元，前值为123.4万美元；每股收益为-0.27美元，前值为-0.57美元。
Marker Therapeutics (MRKR.US): The 2024 Q1 financial report achieved revenue of $1.244 million, previous value of $1.244 million; earnings per share was -0.27 US dollars, previous value of -0.57 US dollars.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.